Key result
Monocrotaline reliably induces pulmonary hypertension and right heart failure in rats over 4 to 6 weeks.
Why the study?
Right heart failure cannot currently be cured, driving the need to better understand the physiological changes causing heart failure under pressure overload.
The monocrotaline rat model is a consistent, non-invasive, and cost-effective preclinical tool for investigating the physiological and cellular mechanisms driving the transition from pulmonary hypertension-induced right ventricular hypertrophy to failure.
Supports the monocrotaline rat model for preclinical PAH studies; leaves open translation to human right heart failure therapies.
Pulmonary artery hypertension (PAH) is characterised by increased pulmonary vascular resistance (PVR) resulting in elevated pressure in the pulmonary artery supplying the pulmonary circulation. Disease of the right ventricle (RV) often manifests as a result of PAH placing excessive pressure on the right side of the heart. Although a relatively rare disease in humans, the impact of sustained PAH is severe, with poor outcomes even in treated individuals. As PAH develops, the blood flow is restricted through the pulmonary arteries and the right ventricle hypertrophies due to the increased strain of pumping blood through the pulmonary circulation. With time, RV hypertrophy progresses to right heart failure, impacting the supply of blood to the left ventricle and systemic circulation. Although right heart failure can currently be treated, it cannot be cured. There is therefore a need for more research into the physiological changes that cause the heart to fail under pressure overload. This review aims to evaluate the monocrotaline (MCT) rat model of PAH as a means of studying the cellular mechanisms associated with the development of RV hypertrophy and right heart failure.
No takes yet. Share an insight, caveat, or question.
Krstic et al. (2024) conducted a review in Pulmonary artery hypertension and right heart disease. Monocrotaline vs. Saline was evaluated. Monocrotaline administration in rats consistently induces pulmonary artery hypertension, right ventricular hypertrophy, and subsequent right heart failure over 4 to 6 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: